Anne Philomena Hyland
Corporate Officer/Principal at London Stock Exchange Plc
Net worth: 39 112 $ as of 29/04/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
John O'Higgins | M | 59 | 4 years | |
Anna Lawrence | F | - | 3 years | |
Dorothée Anna Deuring | F | 55 | 7 years | |
Geertrui Schoolenberg | M | 66 | 2 years | |
Lisa Condron | F | 57 |
London Stock Exchange Plc
London Stock Exchange Plc Investment Banks/BrokersFinance London Stock Exchange Plc, operates as a stock exchange. It offers capital market, trading, information, derivatives, studio, regulatory, enhanced, connectivity, telephone network, reference and historical data, historic price, corporate action, trade data, valuation data, broker ranking, matching and reconciliation. The company was founded in 1571 and is headquartered in London, the United Kingdom. | - |
Paul Waterman | M | 60 | 8 years | |
Ralph Hewins | M | 61 | 8 years | |
Christine Soden | F | 66 | 4 years | |
Hayley Bobrige | M | 42 |
London Stock Exchange Plc
London Stock Exchange Plc Investment Banks/BrokersFinance London Stock Exchange Plc, operates as a stock exchange. It offers capital market, trading, information, derivatives, studio, regulatory, enhanced, connectivity, telephone network, reference and historical data, historic price, corporate action, trade data, valuation data, broker ranking, matching and reconciliation. The company was founded in 1571 and is headquartered in London, the United Kingdom. | - |
Tracy Garrad | F | 54 |
London Stock Exchange Plc
London Stock Exchange Plc Investment Banks/BrokersFinance London Stock Exchange Plc, operates as a stock exchange. It offers capital market, trading, information, derivatives, studio, regulatory, enhanced, connectivity, telephone network, reference and historical data, historic price, corporate action, trade data, valuation data, broker ranking, matching and reconciliation. The company was founded in 1571 and is headquartered in London, the United Kingdom. | - |
Julia Hoggett | F | - |
London Stock Exchange Plc
London Stock Exchange Plc Investment Banks/BrokersFinance London Stock Exchange Plc, operates as a stock exchange. It offers capital market, trading, information, derivatives, studio, regulatory, enhanced, connectivity, telephone network, reference and historical data, historic price, corporate action, trade data, valuation data, broker ranking, matching and reconciliation. The company was founded in 1571 and is headquartered in London, the United Kingdom. | 3 years |
Joe Lupia | M | - | 5 years | |
Rob Fox | M | - | 2 years | |
Samuel Herbert | M | 42 | 4 years | |
Murray Roos | M | 49 |
London Stock Exchange Plc
London Stock Exchange Plc Investment Banks/BrokersFinance London Stock Exchange Plc, operates as a stock exchange. It offers capital market, trading, information, derivatives, studio, regulatory, enhanced, connectivity, telephone network, reference and historical data, historic price, corporate action, trade data, valuation data, broker ranking, matching and reconciliation. The company was founded in 1571 and is headquartered in London, the United Kingdom. | - |
Alasdair Macleod | M | - |
London Stock Exchange Plc
London Stock Exchange Plc Investment Banks/BrokersFinance London Stock Exchange Plc, operates as a stock exchange. It offers capital market, trading, information, derivatives, studio, regulatory, enhanced, connectivity, telephone network, reference and historical data, historic price, corporate action, trade data, valuation data, broker ranking, matching and reconciliation. The company was founded in 1571 and is headquartered in London, the United Kingdom. | - |
Sharon Bowles | F | 71 |
London Stock Exchange Plc
London Stock Exchange Plc Investment Banks/BrokersFinance London Stock Exchange Plc, operates as a stock exchange. It offers capital market, trading, information, derivatives, studio, regulatory, enhanced, connectivity, telephone network, reference and historical data, historic price, corporate action, trade data, valuation data, broker ranking, matching and reconciliation. The company was founded in 1571 and is headquartered in London, the United Kingdom. | - |
Marc J. Yoskowitz | M | - | 2 years | |
Chris Shepherd | M | 59 | 7 years | |
Greville Victor Bell Ward | M | - |
London Stock Exchange Plc
London Stock Exchange Plc Investment Banks/BrokersFinance London Stock Exchange Plc, operates as a stock exchange. It offers capital market, trading, information, derivatives, studio, regulatory, enhanced, connectivity, telephone network, reference and historical data, historic price, corporate action, trade data, valuation data, broker ranking, matching and reconciliation. The company was founded in 1571 and is headquartered in London, the United Kingdom. | - |
Eric James Boyle | M | 69 |
London Stock Exchange Plc
London Stock Exchange Plc Investment Banks/BrokersFinance London Stock Exchange Plc, operates as a stock exchange. It offers capital market, trading, information, derivatives, studio, regulatory, enhanced, connectivity, telephone network, reference and historical data, historic price, corporate action, trade data, valuation data, broker ranking, matching and reconciliation. The company was founded in 1571 and is headquartered in London, the United Kingdom. | 42 years |
Annalisa Jenkins | M | 58 | 2 years | |
Stephen O'Connor | M | 63 |
London Stock Exchange Plc
London Stock Exchange Plc Investment Banks/BrokersFinance London Stock Exchange Plc, operates as a stock exchange. It offers capital market, trading, information, derivatives, studio, regulatory, enhanced, connectivity, telephone network, reference and historical data, historic price, corporate action, trade data, valuation data, broker ranking, matching and reconciliation. The company was founded in 1571 and is headquartered in London, the United Kingdom. | - |
Justin Roberts | M | - | 2 years | |
Kevin Boyd | M | 59 |
London Stock Exchange Plc
London Stock Exchange Plc Investment Banks/BrokersFinance London Stock Exchange Plc, operates as a stock exchange. It offers capital market, trading, information, derivatives, studio, regulatory, enhanced, connectivity, telephone network, reference and historical data, historic price, corporate action, trade data, valuation data, broker ranking, matching and reconciliation. The company was founded in 1571 and is headquartered in London, the United Kingdom. | - |
Frank Lucas | M | 55 |
London Stock Exchange Plc
London Stock Exchange Plc Investment Banks/BrokersFinance London Stock Exchange Plc, operates as a stock exchange. It offers capital market, trading, information, derivatives, studio, regulatory, enhanced, connectivity, telephone network, reference and historical data, historic price, corporate action, trade data, valuation data, broker ranking, matching and reconciliation. The company was founded in 1571 and is headquartered in London, the United Kingdom. | - |
Alf Gunnar Martin Nicklasson | M | 69 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 7 years |
Ian Weaver | M | - |
London Stock Exchange Plc
London Stock Exchange Plc Investment Banks/BrokersFinance London Stock Exchange Plc, operates as a stock exchange. It offers capital market, trading, information, derivatives, studio, regulatory, enhanced, connectivity, telephone network, reference and historical data, historic price, corporate action, trade data, valuation data, broker ranking, matching and reconciliation. The company was founded in 1571 and is headquartered in London, the United Kingdom. | 49 years |
Michael Findlay | M | 56 |
London Stock Exchange Plc
London Stock Exchange Plc Investment Banks/BrokersFinance London Stock Exchange Plc, operates as a stock exchange. It offers capital market, trading, information, derivatives, studio, regulatory, enhanced, connectivity, telephone network, reference and historical data, historic price, corporate action, trade data, valuation data, broker ranking, matching and reconciliation. The company was founded in 1571 and is headquartered in London, the United Kingdom. | 4 years |
Daniel Shames | M | - | 2 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Christopher Paul Blackwell | M | 62 | 13 years | |
Alastair MacKinnon | M | 53 | 7 years | |
Andrew Duff | M | 65 | 7 years | |
Ian Brindle | M | 80 | 9 years | |
John Brown | M | 69 | 12 years | |
Peter John Fellner | M | 80 | 7 years | |
Elmar Schnee | M | 65 | 1 years | |
Paul Oliver | M | - | 8 years | |
Martin John Shott | M | 72 | - | |
Sharon Curran | F | 56 | 1 years | |
Andrew Richards | M | 64 | 11 years | |
Steve Good Good | M | 63 | 10 years | |
Sandra Lynne Boss | F | 57 | 3 years | |
Susan Foden | M | 71 | - | |
Neil William Warner | M | 70 | 9 years | |
Nicholas Keher | M | 42 | 2 years | |
Simon Sturge | M | 65 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 2 years |
Brian G. Taylorson | M | 68 | 14 years | |
Martin Abell | M | - | 4 years | |
John Hartup | M | 73 | 9 years | |
Trevor Phillips | M | 63 | 7 years | |
Ian Johnson | M | 71 | 1 years | |
David W. Dutro | M | 68 | 18 years | |
Nick Salmon Salmon | M | 72 | 6 years | |
Robert G. Beeston | M | 82 | 7 years | |
Ian James Nicholson | M | 64 | 9 years | |
David Chiswell | M | 70 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 4 years |
Peter Allen | M | 68 | 9 years | |
Andrew Christie | M | 69 | 9 years | |
Christopher Girling | M | 70 | 8 years | |
Kevin Roger Kenneth Matthews | M | 60 | 9 years | |
Abdul Mullick | M | - | - | |
Jenny Yip | F | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 5 years |
Robert Sklans | M | - | 2 years | |
Johann Willemse | M | - | - | |
Timothy Wright | M | 63 | 11 years | |
Greg Bellotti | M | - | 9 years | |
Wendi Weber | M | - | 2 years | |
Rob Mangold | M | - | - | |
Laura Ann Maria Higgins | F | 47 | 4 years | |
John N. Staniforth | M | 70 | 7 years | |
Ajeeth Enjeti | M | - | 3 years | |
Mark Jonathan Main | M | 64 | - | |
Arndt Justus Georg Schottelius | M | 58 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Catherine Moukheibir | F | 64 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 2 years |
Rohan Saikia | M | - | 2 years | |
Alan Keith Boyd | M | 70 | 4 years | |
Roger Heerman | M | - | 10 years | |
Wai Wong | M | 50 | 11 years | |
Colin Clive Dalton | M | 74 | - | |
Karl Keegan | M | 57 | 4 years | |
Jean-Michel Cossery | M | 65 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 3 years |
Brian Schwartz | M | 52 | 2 years | |
Nuala Brennan | F | 55 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 5 years |
Statistics
Country | Connections | % of total |
---|---|---|
United Kingdom | 84 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Anne Philomena Hyland
- Personal Network